Comparative Pharmacology
Head-to-head clinical analysis: BRIXADI versus TALWIN NX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIXADI versus TALWIN NX.
BRIXADI vs TALWIN NX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Pentazocine is a mixed agonist-antagonist opioid analgesic that acts as an agonist at kappa opioid receptors and as an antagonist or partial agonist at mu opioid receptors. Naloxone is added to prevent intravenous abuse but has no oral bioavailability.
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
1 tablet (pentazocine 50 mg/naloxone 0.5 mg) orally every 3-4 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
2-3 hours (terminal) for pentazocine; naloxone half-life 1-1.5 hours. Clinically, duration limited by pentazocine's shorter half-life.
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Renal: ~60% as unchanged drug and glucuronide conjugates. Biliary/fecal: ~20% as metabolites. Total: 80% eliminated within 72 hours.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist/Antagonist